A reliable biomarker for HIV-associated dementia (HIV-D) has eluded neuro-AIDS investigators for more than 2 decades. An urgent need remains, because although the incidence of HIV-D has declined among patients treated with highly active antiretroviral therapy, prevalence has increased, and a more insidious cognitive decline, minor cognitive motor disorder (MC/MD), has become common. 1, 2 Efforts to diagnose, evaluate treatments, and identify risk factors are held back by lack of diseasespecific biomarkers. Routine radiographic findings of "HIV encephalitis" do not correlate strongly with cognitive dysfunction, and although advanced imaging modalities such as magnetic resonance spectroscopy (MRS), magnetization transfer imaging, and diffusion tensor imaging show promising, sometimes striking, correlations, these modalities will likely remain impractical in most settings where costs are prohibitive and interpretive expertise is limited. [3] [4] [5] An ideal biomarker for HIV-associated brain disease would be objective, quantitative, and scalable for wide use. Operationally, it would serve 1) diagnosis of HIV-D and MC/MD, 2) identification of patients at risk, 3) detection of disease progression, 4) confirmation of arrested or static encephalopathy, and 5) measurement of treatment response. A single biomarker sufficient for all these aims is implausible; rather, complementary markers likely will be required.
Moving from bedside to bench, biomarkers ideally should further the science of neuro-AIDS by means of transparent associations with HIV neuropathogenesis. Numerous viral and host factors have been implicated; how these elements interact and converge to produce the particular patterns of HIVassociated brain injury remains unclear. The most attractive grand narrative is also the oldest, namely, that brain injury in HIV is driven by immunopathology. Monocyte-derived macrophages (MDMs) traffic between blood and brain early in infection, carry virus into the CNS, activate other immune cells, amplify inflammation, and secrete potent neurotoxins. 6 In the battle with HIV, neuronal tissue injury and cell death are a consequence of immunologic "friendly fire."
Neuro-AIDS investigators have focused largely on the CSF as a source of biomarkers in the belief that this compartment represents a window onto the brain microenvironment. CSF macromolecular analysis has led to reasonably sensitive and specific biomarkers for dementia of the Alzheimer type (DAT). 7 Progress, however, was directed by pathognomonic brain lesions: the senile plaques of filamentous ␤-amyloid, and neurofibrillary tangles of hyperphosphorylated tau protein. Unfortunately, the HIV-diseased brain has not been so cooperative. No lesions reliably distinguish patients with clinical dementia from those with preserved cognitive function. 8 Biomarker research has relied on identifying signature molecules of brain injury pathways familiar from other diseases, e.g., stroke, epilepsy, Alzheimer disease (AD), Parkinson disease. Hence, it is not surprising that proposed neuro-AIDS disease mechanisms, such as oxidative stress, neuroinflammation, and excitotoxicity, are common to many brain diseases. It is also not surprising that unique or diseasespecific biomarkers remain elusive.
Two studies reported in this issue of Neurology ® illustrate uses of CSF biomarkers in HIV-infected patients with cognitive impairment. Schifitto et al. 9 investigate treatment effect of selegiline, a drug with antioxidant properties, on CSF protein carbonyls, markers of oxidative stress. Clifford et al. 10 compare AD biomarkers in cognitively impaired HIV-infected patients, controls, and patients with mild DAT.
Schifitto et al. summarize data from a substudy of seropositive subjects with cognitive impairment who participated in a 24-week trial of selegiline, 3 or 6 mg/d, vs placebo. As previously reported, no benefit of selegiline was seen on cognitive outcomes or functional measures. 11 Of 128 subjects enrolled, 62 underwent MRS at baseline and weeks 12 and 24, whereas 47 subjects provided CSF samples at base-line and week 24. Only 11 selegiline-treated and 8 placebo-treated subjects had both CSF and MRS evaluations at baseline, limiting interpretation of MRS and CSF biomarker correlations. The authors hypothesized that despite a negative clinical trial, protein carbonyl or MRS analysis might reveal physiologic drug effects. This was not the case, and the current substudy report corroborates lack of drug effect: 3 strikes for selegiline. A type II error (false negative), although not impossible, is unlikely.
As the HIV-infected population ages, AD is entering the differential diagnosis of patients presenting with cognitive symptoms, with important treatment implications. Clifford et al. analyzed CSF from 49 subjects with HIV-associated cognitive impairment; 21 seropositive, cognitively normal subjects; 68 with mild DAT; and 50 controls. CSF ␤-amyloid , ␤-amyloid , and total and phosphorylated tau (P-tau 181 ) were measured. The notable finding was that subjects with HIV and cognitive impairment (HIV-associated neurologic disorders [HAND] ) and subjects with mild DAT had similarly low ␤-amyloid levels. These data support previous CSF and neuropathologic findings suggesting that abnormal A␤ 42 metabolism may be a factor in HIVassociated brain disease. In vitro evidence indicates that HIV Tat protein can inhibit neprilysin, a membrane metalloendopeptidase involved in A␤ breakdown, and also may interact with lipoprotein receptor-related protein to reduce A␤ clearance from CSF. 12 Low levels of tau and P-tau 181 distinguished samples from subjects with HAND from those with DAT, who had the expected high tau levels. The authors propose CSF tau measurement as a way to differentiate HIV-associated cognitive impairment from mild DAT in appropriately selected patients.
The CSF markers investigated in these 2 studies, although not specific for HIV-D, were useful in corroborating lack of treatment effect and in sharpening differential diagnosis, respectively. These results have important clinical implications. However, the greatest clinical advances likely await disease-specific markers. To achieve these advances, perhaps it is time to revisit whether CSF remains the most promising compartment for HIV-D biomarker research. This window on the brain has not, in the case of HIV, brought in much light. Given the trafficking of key effector cells-the MDMs-the blood compartment may not only be more accessible but also more informative. Enabling technologies have made possible analysis of complex protein constituents in blood. For example, peripheral blood MDM lysates have been phenotypically profiled, or "fingerprinted," using retentate chromatography and mass spectrometry. In one study, a protein peak was identified that successfully discriminated HIV-positive subjects with well-characterized cognitive impairment (CI) from those with preserved cognition (NC) and controls. Sensitivity and specificity in this relatively small (n ϭ 31) sample were 100% and 75%, respectively. 13 In a later study, the same group performed similar proteomic analysis on CSF samples from subjects with CI and NC from the same cohort. Several proteins involved in cell signaling, phagocytosis, and cell-matrix interactions were identified from pooled samples that distinguished the CI group from the NC group.
14 Unfortunately, low CSF protein concentrations and sample volumes limit comparison of individual samples at this time. In fact, regardless of compartment, daunting technical challenges remain for proteomics and other high-content "-omics," e.g., lipidomics, transcriptomics, metabolomics, that are applicable to neuro-AIDS research. These approaches nevertheless offer new insights into virushost interactions and may consequently open new windows into the neuropathogenesis of HIV. Early results raise hope that disease-specific biomarkers will emerge to meet the pressing needs of clinicians and afflicted patients.
